Please enter your license information:
Efficacy Profile
A1C across renal functions visual full text
- A visual of 4 downward arrows displaying demonstrated A1C findings in patients with normal, mild, moderate and severe renal impairment.
- The first three arrows are associated with Study 1: pooled analysis at Week 24.
- Arrow 1 is associated with normal renal function (eGFR ≥90 mL/min) with a demonstrated reduction in A1C of -0.61%, p<0.0001. Change from baseline was -0.68% for Trajenta® (n=1,006) and -0.08% for placebo (n=406).
- Arrow 2 is associated with mild renal impairment (eGFR 60 to <90 mL/min) with a demonstrated reduction in A1C of -0.63, p<0.0001. Change from baseline was -0.72% for Trajenta® (n=715) and -0.11% for placebo (n=272).
- Arrow 3 is associated with moderate renal impairment (eGFR 30 to <60 mL/min) with a demonstrated reduction in A1C of -0.52, p=0.0023. Change from baseline was -0.78% for Trajenta® (n=80) and -0.21 for placebo (n=29).
- The fourth arrow is associated with Study 2: RCT at Week 12.
- Arrow 4 is associated with severe renal impairment (eGFR <30 mL/min) with a demonstrated A1C reduction of -0.59%, p<0.0001. Change from baseline was -0.76% for Trajenta® (n=68) and -0.15% for placebo (n=65).
Are you thinking Trajenta®?
![Healthcare professional and patient Healthcare professional and patient](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/login-banner-updated.png)
Are you a Canadian
View coverage details for Trajenta® and Jentadueto®
![Map of Canada Map of Canada](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/check-coverage-icon.png)